Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03017131 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL: Aldesleukin
DRUG: Cyclophosphamide
DRUG: Decitabine
BIOLOGICAL: Genetically Engineered NY-ESO-1-specific T Lymphocytes
OTHER: Laboratory Biomarker Analysis

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]